Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become…
Infex appoints Lonza to manufacture new lung infection drug
Alderley Park, Cheshire Infex Therapeutics has awarded a £1m contract to Lonza…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help…
Infex focuses on pandemic preparedness with Covid patent
Infex Therapeutics has filed for a UK patent for a novel therapy designed to…
Infex Therapeutics and LifeArc in Collaboration to Defeat Superbugs
Infex Therapeutics has combined forces with medical research charity, LifeArc,…